XML 14 R4.htm IDEA: XBRL DOCUMENT v3.20.2
CONSOLIDATED CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (UNAUDITED) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2020
Jun. 30, 2019
Jun. 30, 2020
Jun. 30, 2019
Development revenues:        
Government contracts and other $ 185 $ 302 $ 303 $ 1,039
Operating expenses:        
Research and development 327 1,289 1,268 2,715
Sales and marketing 105 97 215 211
General and administrative 1,324 875 2,832 2,237
Total operating expenses 2,537 2,261 5,096 5,163
Operating loss (2,352) (1,959) (4,793) (4,124)
Other income (expense):        
Interest income 9 7 45 14
Interest expense (252) (597) (601) (1,111)
Change in fair value of warrants 756 282 2,423 492
Total other income (expense) 513 (308) 1,867 (605)
Loss from continuing operations (1,839) (2,267) (2,926) (4,729)
Loss from discontinued operations   (6,880)   (7,568)
Net loss $ (1,839) $ (9,147) $ (2,926) $ (12,297)
Basic and diluted net loss per share attributable to common stockholders - continuing operations $ (0.45) $ (5.12) $ (0.74) $ (11.89)
Basic and diluted net loss per share attributable to common stockholders - discontinued operations   (15.55)   (19.02)
Net loss per share, basis and diluted $ (0.45) $ (20.67) $ (0.74) $ (30.91)
Basic and diluted weighted average shares used in calculating net loss per share attributable to common stockholders 4,053,242 442,512 3,967,392 397,827
In Process Research and Development [Member] | Nano Tx Therapeutics [Member]        
Operating expenses:        
Research and development $ 781   $ 781